Nature of the Disclosure
This is a regulatory disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing the stock exchanges of the allotment of Non-Convertible Debentures (NCDs) on a private placement basis.
Key Quantitative Figures and Transaction Details
The Finance Committee of Jubilant Pharmova Limited, at its meeting held on November 5, 2026, at 07:30 P.M. (IST), approved the allotment of the following:
- Number of NCDs: 80,000
- Face Value per NCD: ₹1,00,000
- Total Issue Size: ₹800 Crore
- Type of Instrument: Unsecured, Rated, Listed, Redeemable Non-Convertible Debentures
- Issue Price: Issued at par
- Coupon/Interest Rate: 8.50% per annum
- Tenure: 3 Years
- Date of Allotment: November 5, 2026
- Date of Maturity: November 5, 2028
Parties Involved and Listing Details
The NCDs were allotted to successful bidders on a private placement basis. The instruments are proposed to be listed on the BSE Limited.
Security and Other Features
The debentures are unsecured, meaning no charge or security has been created over any assets. There are no special rights, interests, or privileges attached to the instrument. The schedule of payment of coupon/interest and principal is detailed in the Key Information Document, which is referenced but not enclosed in this filing.
Additional Information
The company states that there has been no delay in payment of interest/principal for more than three months or default in payment (NA). There are no details of any letters or comments regarding payment/non-payment. Details of redemption are covered in the tenure and maturity date provided.
This intimation has been uploaded on the company's website at www.jubilantpharmova.com.